Connor, Clark & Lunn Investment Management Ltd.

Position in ARWR — Arrowhead Pharmaceuticals, Inc.

CIK 1596800 VANCOUVER, A1

Position in ARWR

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$50,990,129

-$1,488,579 QoQ

Shares Held

625,569

-25.3% QoQ

Ownership

0.443%

of shares outstanding

% of Portfolio

0.10%

of 13F equity value

Holder Rank

#35

of 497 holders

Holding Since

Jun 2021

11 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $650,455,382 across 105 Biotechnology names. ARWR ranks #3 (7.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	135,236	$67,175,777
2	IONS	Ionis Pharmaceuticals Inc	684,236	$54,253,072
3	ARWR	Arrowhead Pharmaceuticals, Inc. This page	625,569	$50,990,129
4	MIRM	Mirum Pharmaceuticals, Inc.	420,063	$49,176,775
5	REGN	Regeneron Pharmaceuticals, Inc.	42,465	$26,478,625
6	AXSM	Axsome Therapeutics, Inc.	97,698	$23,913,539
7	INSM	INSMED Inc	212,676	$22,675,515
8	VKTX	Viking Therapeutics, Inc.	530,607	$20,698,979

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$50,990,129	625,569	-25.3%	Shares	Sole	2026-08-13
2026-03-31	$52,478,708	836,981	+26.2%	Shares	Sole	2026-05-11
2025-12-31	$44,033,964	663,262	+432.6%	Shares	Sole	2026-02-10
2025-09-30	$4,295,005	124,529	+618.2%	Shares	Sole	2025-11-13
2022-12-31	$703,310	17,340	-63.0%	Shares	Sole	2023-02-10
2022-09-30	$1,548,161	46,843	-46.0%	Shares	Sole	2022-11-10
2022-06-30	$3,055,981	86,793	+30.6%	Shares	Sole	2022-08-05
2022-03-31	$3,057,139	66,474	+108.5%	Shares	Sole	2022-05-12
2021-12-31	$2,113,511	31,878	-51.9%	Shares	Sole	2022-02-10
2021-09-30	$4,141,793	66,343	+89.7%	Shares	Sole	2021-11-12
2021-06-30	$2,896,215	34,970	—	Shares	Sole	2021-08-12
No filing history on record for this holder in this stock.